Piriyaporn Chongtrakool

Piriyaporn Chongtrakool

Auto-generated profile, based on publicly available information

Piriyaporn Chongtrakool

Department of Microbiology, Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2023 in Frontiers in Public Health
Verified
Journal Article
Open access
Thundon NgamprasertchaiThundon Ngamprasertchai
Thundon Ngamprasertchai
CKChayanis Kositamongkol
Chayanis Kositamongkol
Saranath LawpoolsriSaranath Lawpoolsri
Saranath Lawpoolsri
Pinyo RattanaumpawanPinyo Rattanaumpawan
Pinyo Rattanaumpawan
Viravarn LuviraViravarn Luvira
Viravarn Luvira
PPPochamana Phisalprapa
Pochamana Phisalprapa
Introduction: This study aims to assess the economic impact of introducing the 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) to Thai older adult aged ≥ 65 years who are healthy or with chronic health conditions and immunocompromised conditions from a societal perspective in order to introduce the vaccine to Thailand’s National Immunization Program for the older adult.Methods: A Markov model was adopted to simulate the natural history and economic outcomes of invasive pneumococcal diseases using updated published sources and Thai databases. We reported analyses as incremental cost-effectiveness ratios (ICER) in USD per quality-adjusted life year (QALY) gained. In addition, sensitivity analyses and budget impact analyses were conducted.Results: The base-case analysis of all interventions (no vaccinations [current standard of care in Thailand], PPSV23, and PCV13) showed that PPSV23 was extendedly dominated by PCV13. Among healthy individuals or those with chronic health conditions, ICER for PCV13 was 233.63 USD/QALY; meanwhile, among individuals with immunocompromised conditions, ICER for PCV13 was 627.24 USD/QALY. PCV13 are economical vaccine for all older adult Thai individuals when compared to all interventions.Conclusions: In the context of Thailand, PCV13 is recommended as the best buy and should be primarily prioritized when both costs and benefits are considered. Also, this model will be beneficial to the two-next generation pneumococcal vaccines implementation in Thailand.

1 February 2020 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
SPSujiraphong Pharkjaksu
Sujiraphong Pharkjaksu
PCPiriyaporn Chongtrakool
Piriyaporn Chongtrakool
MCMethee Chayakulkeeree
Methee Chayakulkeeree
CMChalermchai Mitrpant
Chalermchai Mitrpant
PAPornpimon Angkasekwinai
Pornpimon Angkasekwinai
PNPopchai Ngamskulrungroj
Popchai Ngamskulrungroj
Introduction: The Cryptococcus neoformans/gattii species complexes are a leading cause of fatality among HIV-infected patients. Despite the unavailability of clinical breakpoints (CBPs) for antifungal agents, epidemiological cutoff values (ECVs) were recently proposed, and non-wild-type isolates for polyenes and azoles are being increasingly reported. However, the distributions of the susceptibility patterns for pre-HIV-era isolates have not been studied. Methods: We determined the in vitro antifungal susceptibility patterns of 233 Cryptococcus isolates, collected at the National Institutes of Health, USA, in pre-HIV pandemic era, to study minimum inhibitory concentrations (MICs) to the important drugs for cryptococcosis and to compare the results with strain genotypes. Amphotericin B susceptibility was compared to published ECV of C. neoformans. Results: The 233 Cryptococcus strains consisted of 89.7% C. neoformans species complex and 10.3% C. gattii species complex. Most were from clinical sources (189, 81.1%), and the major molecular type was VNI (146, 62.7%). The highest geometric mean (GM) was observed for fluconazole (GM = 0.96 μg/mL) while the lowest was for itraconazole (GM = 0.10 μg/mL). MICs to fluconazole in C. gattii species complex were significantly higher than C. neoformans species complex (p < 0.001). Moreover, C. neoformans/VNI strains showed significantly higher MICs than others such as C. neoformans/VNII to fluconazole (p < 0.0001) and C. deneoformans/VNIV to amphotericin B (p = 0.022) and fluconazole (p = 0.008). In our collection of 167 clinical C. neoformans species complex strains, 85 (50.9%), 24 (14.4%), and 3 (1.8%) strains had an amphotericin B (AMB)-MIC of 1, 2, and 4 μg/mL, respectively. The high percentage (66.9%, 79/118 strains) of non-wild-type clinical C. neoformans VNI strains, using an AMB-ECV of 0.5 μg/mL, was found. Moreover, 25 of 28 (89.3%) C. neoformans VNI strains from environmental and veterinary sources also had AMB-MICs above 0.5 μg/mL. In general, there was no significant difference in GM AMB-MIC of the clinical strains isolated from patients with (35 patients) and without (78 patients) prior AMB treatment (0.85 vs 0.76; p = 0.624). GM MIC of the environmental strains was not significantly different from that of the prior AMB-treatment strains (0.98 vs 0.76, p = 0.159) and the post-AMB-treatment strains (0.98 vs 0.85, p = 0.488). Conclusion: The high rate of non-wild-type among these otherwise naive isolates to amphotericin B is unexpected. Confirmation with more strains from a later era is needed.

1 March 2021 in Journal of Medical Mycology
Verified
Journal Article
Open access
ZHZin Htun
Zin Htun
ALAree Laikul
Aree Laikul
WPWatcharapol Pathomsakulwong
Watcharapol Pathomsakulwong
CYChompoonek Yurayart
Chompoonek Yurayart
TLT. Lohnoo
T. Lohnoo
Theerapong KrajaejunTheerapong Krajaejun
Theerapong Krajaejun
Pythium insidiosum causes a life-threatening infection termed pythiosis in humans and other animals. The organism has been identified in tropical and subtropical environments worldwide. Since 1985, human pythiosis has been increasingly reported from Thailand. Seroprevalence studies estimated that 32,000 Thai people had been exposed to the pathogen. In 2018, the first animal pythiosis case in Thailand was diagnosed in a horse. Here, we investigated the seroprevalence of anti-P. insidiosum antibodies in the Thai equine population. We surveyed serum anti-P. insidiosum antibodies in 150 horses distributed across Thailand, using three established serological tests: enzyme-linked immunosorbent assay (ELISA), immunochromatographic test (ICT), and Western blot analysis. ELISA detected the anti-P. insidiosum antibodies in three horses. ICT and Western blot confirmed the presence of the antibodies in one of the ELISA-positive horses. Based on one positive out of 150 horses tested, the seroprevalence of anti-P. insidiosum antibodies in the Thai equine population was 0.7%, which is markedly higher than that in the Thai human population (0.07%), but much lower than that in the Brazilian equine population (11.1%). The seroprevalence of the anti-P. insidiosum antibodies in the equine population suggests a higher incidence of pythiosis in horses than in humans. The antibody surveillance reported by our group was undertaken to promote a better understanding of the epidemiology and host susceptibility of pythiosis in Thailand.

21 July 2025 in Mycoses
Verified
Journal Article
Open access
NPNantaporn Pirogard
Nantaporn Pirogard
PCPiriyaporn Chongtrakool
Piriyaporn Chongtrakool
DLDarunee Lertsudkanung
Darunee Lertsudkanung
MCMethee Chayakulkeeree
Methee Chayakulkeeree
Introduction: Invasive candidiasis is a life‐threatening fungal infection associated with high mortality rates. Adherence to clinical practice guidelines (CPG) has been shown to improve patient outcomes. This study aimed to evaluate physician compliance with CPG following the implementation of care bundles and locally developed CPG and to assess the impact of CPG implementation on patient mortality. Methods: This quasi‐experimental study utilised a historical cohort control design. Candidemia patients treated at Siriraj Hospital in Bangkok, Thailand, from November 2021 to April 2024 were enrolled. A prospective cohort group received CPG for invasive candidiasis, modified from ESCMID recommendations, covering eight facets. Education care bundles, including clinical policy, training, infographic sheets, leaflets and SMS alerts, were also implemented. Each CPG item was scored as 0, 1 or 2, representing non‐compliance, partial compliance and full compliance, respectively. A total compliance score below eight indicates poor compliance. Physician compliance and 30‐day mortality rates were analysed. Results: A total of 112 patients were included in the study: 56 in the historical control group and 56 in the prospective intervention group. Both groups exhibited similar baseline characteristics and risk factors for candidemia. Following the implementation of the CPG and care bundles, physician compliance significantly improved across several metrics. Notable increases were observed in: initiating anti‐fungal therapy within 24 h (OR = 6.00, 95% CI [2.41–14.96], p < 0.001), receipt of appropriate anti‐fungal therapy, specifically with echinocandins or amphotericin B (OR = 9.17, 95% CI [1.11–75.96], p = 0.03), catheter removal or source control within 48 h (OR = 37.17, 95% CI [4.68–295.39], p < 0.001), obtaining blood cultures at least every other day (OR = 19.15, 95% CI [7.35–49.86], p < 0.001), continuing anti‐fungal therapy for at least 14 days after the first negative culture (OR = 3.30, 95% CI [1.42–7.67], p = 0.005), conducting echocardiography (0% vs. 16.1%, p = 0.003), performing fundoscopy (OR = 5.24, 95% CI [1.79–15.30], p = 0.001). There was a significant improvement in compliance scores, with ≥ 8 being more prevalent in the intervention group compared to controls (OR = 5.39, 95% CI [1.98–14.69], p < 0.001). The mean compliance score was 8 ± 2 in the control group and 11 ± 2 in the intervention group ( p < 0.001). Additionally, the all‐cause 30‐day mortality rate decreased significantly from 55.4% in the control group to 35.7% in the intervention group (OR = 0.45, 95% CI [0.21–0.96], p = 0.04). Conclusions: The implementation of CPG and care bundles for invasive candidiasis significantly enhanced physician compliance and improved patient survival. These findings support the continued adoption of CPG and care bundles in the management of invasive candidiasis.

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
NSNaruemit Sayabovorn
Naruemit Sayabovorn
PCPiriyaporn Chongtrakool
Piriyaporn Chongtrakool
SRSiriporn Rachakhom
Siriporn Rachakhom
SKSupaporn Kaewsomnuck
Supaporn Kaewsomnuck
RWRakkan Wejsuwanmanee
Rakkan Wejsuwanmanee
AJAnupop Jitmuang
Anupop Jitmuang
Blood culture (BC) is a standard diagnostic testing of bloodstream infection. Inappropriate blood sampling may lead to BC contamination causing antimicrobial overuse and adverse outcomes. Several individualized interventions during blood sampling are applied to reduce BC contamination. However, the efficacy of a multifaceted intervention applied to nursing staff for reducing the contamination rate has yet to be thoroughly studied. From August 2020–January 2021, we conducted a 1:1 cluster-randomized controlled trial in 6 medical and 6 surgery wards. Six wards (3 medical, 3 surgery) as the intervention arm received the multifaceted intervention comprising a multimodal educational program, regular surveillance, and feedback. The other six wards (3 medical, 3 surgery) as the control arm received standard care. Participant nurses responsible for BC collection had to answer the pre- and post-study questionnaires to score their background knowledge on appropriate BC sampling. Clinical data and microbiological results were also collected. Of 3,630 blood culture bottles, 304 (8.4%) were culture positive, with an equal number of true bacteremia and contaminated bottles in both arms. The pre-study contamination rate was 2.2-2.5%. After applying the interventions, the contamination rate was 2.3% in the intervention arm and 3.2% in the control arm (p=0.535). Coagulase-negative staphylococci were the most common contaminants (12.8%). Factors associated with contaminated BC included pulmonary diseases (p=0.006), length of hospital stay (p=0.004), blood sampling at 7:00-15:00 (p=0.001), and delayed time to positivity (23.49 h, p< 0.001). In addition, nurses who received the interventions achieved overall scores in post-study questionnaires significantly more than nurses who did not (p< 0.001). The multifaceted intervention can maintain a lower contamination rate throughout the study period. It may be a strategy to improve knowledge of an appropriate BC collection for medical staff. This study demonstrated that comorbidity, length of hospitalization, time of blood sampling, and time to culture positivity likely influenced BC contamination. All Authors: No reported disclosures